Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Commercial Officer | May 14, 2021 | May 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date May 14, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 7,209 |
Reported balance
After 2021-05-14 transaction · row 1
1 source rowRow 1 · 2021-05-14 · Sale · Disposed 3,462 · Balance 7,209 F1: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.40 to $55.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.40 to $55.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2021 Filed May 18, 2021 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,462 | $55.41 | $191,829.42 |
DisclosureSEC source: 0001439222-21-000041 · wf-form4_162136864414651.xml · nonDerivative · entry 1 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.40 to $55.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2021 Filed Mar 16, 2021 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 500 | $48.58 | $24,290.00 |
DisclosureSEC source: 0001439222-21-000031 · wf-form4_161592564145666.xml · nonDerivative · entry 2 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,671 Read SEC document |
| March 01, 2021 Filed Mar 16, 2021 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,200 | $47.99 | $105,578.00 |
DisclosureSEC source: 0001439222-21-000031 · wf-form4_161592564145666.xml · nonDerivative · entry 1 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,171 F1 · balance_after: Includes 314 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000023 · wf-form4_161420118102035.xml · derivative · entry 3 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724 Underlying: Common stock · 725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 215 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000023 · wf-form4_161420118102035.xml · nonDerivative · entry 2 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,057 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000023 · wf-form4_161420118102035.xml · nonDerivative · entry 1 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000013 · wf-form4_161359645668070.xml · derivative · entry 5 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000013 · wf-form4_161359645668070.xml · nonDerivative · entry 3 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,547 Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000013 · wf-form4_161359645668070.xml · nonDerivative · entry 2 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000013 · wf-form4_161359645668070.xml · derivative · entry 4 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,334 Underlying: Common stock · 8,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000013 · wf-form4_161359645668070.xml · nonDerivative · entry 1 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantCommon stock · Derivative | 44,000 | $0.00 Strike: $56.68 | $0.00 |
DisclosureSEC source: 0001439222-21-000008 · wf-form4_161316505175434.xml · derivative · entry 2 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common stock · 44,000 shares Expires 2031-02-10 F3 · derivative.exercise_date: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000008 · wf-form4_161316505175434.xml · derivative · entry 1 Miles Darrin · CIK 0001840076 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common stock · 11,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.